Clinical Trials Logo

Clinical Trial Summary

This study determines whether non-invasive evaluation using repeated magnetic resonance imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes in a person's mental functions that result from radiation exposure to the brain. This study may let researchers monitor patient responses to treatment and the disease better and possibly make changes to patient treatment, if needed.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To describe changes of image features on conventional T1- and T2- weighted imaging, and quantitative changes on multiparametric MRI including apparent diffusion coefficient (ADC), fractional anisotropy (FA), relative cerebral blood volume (rCBV), fractional volume of the extravascular, extracellular space (ve) and Ktrans (transfer constant that characterizes the diffusive transport of low-molecular weight gadolinium across the capillary endothelium) associated with neurocognitive changes following radiation. SECONDARY OBJECTIVES: I. To identify biofluid biomarkers at baseline and dynamics of biomarkers after radiation exposure that are associated with neurocognitive changes. II. To model a composite early biomarker (baseline or within 3 weeks of the start of radiotherapy) that incorporates the most promising imaging and biofluid biomarkers to predict for later neurocognitive decline. III. To evaluate the relationship between the delivered radiation dosimetry to brain subregions and patterns of neurocognitive decline in order to inform potential subregions of focus for future pre-clinical and clinical investigation. IV. To evaluate the relationship between quantitative changes on multiparametric MRI including apparent diffusion coefficient (ADC), fractional anisotropy (FA), relative cerebral blood volume (rCBV), fractional volume of the extravascular, extracellular space (ve) and Ktrans (transfer constant that characterizes the diffusive transport of low-molecular weight gadolinium across the capillary endothelium) with radiation dosimetry. EXPLORATORY OBJECTIVE: I. To explore changes on advanced MR measurements of structural connectomics, functional connectomics, working memory network, cerebrovascular reactivity (CVR), cerebral blood flow (CBF) and brain metabolism associated with neurocognitive changes following radiation. OUTLINE: Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy, and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo functional MRI at baseline and 6 months post-radiotherapy. Patients also complete questionnaires and undergo collection of blood samples at baseline, weekly through week 6 during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05087888
Study type Observational
Source M.D. Anderson Cancer Center
Contact Caroline Chung
Phone 713-563-2300
Email cchung3@mdanderson.org
Status Recruiting
Phase
Start date August 22, 2019
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT00001972 - PET Scan of Brain Metabolism in Relation to Age and Disease N/A
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Terminated NCT02855086 - Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Phase 1/Phase 2
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Withdrawn NCT03234309 - Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors Phase 2
Completed NCT00178295 - Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury N/A
Recruiting NCT04810871 - Surgical Resection of Latent Brain Tumors Prior to Recurrence N/A
Recruiting NCT02800486 - Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Phase 2
Completed NCT01621295 - Assessing the Patient Experience in Cancer Care N/A
Completed NCT02964416 - Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Phase 4
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT00040573 - Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. Phase 1/Phase 2
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Recruiting NCT02754544 - Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors N/A
Recruiting NCT03216148 - 18F-FET PET in Childhood Brain Tumours Phase 2
Completed NCT00001171 - Evaluation of Factors in Human Brain Tumors N/A
Withdrawn NCT01413438 - Bevacizumab With or Without Surgery for Adult Glioblastomas Phase 2
Not yet recruiting NCT05516485 - Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography N/A
Recruiting NCT02639325 - Tumor Related Epilepsy